CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population

Cancer Epidemiology

Volumn 36, Issue 5, 2012, Pages 453-457

  Bayram, Süleyman ^a   Topaktaş, Mehmet ^b   Akkiz, Hikmet ^b   Bekar, Aynur ^b   Akgöllü, Ersin ^b  

^a ADIYAMAN UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

CHEK2; CHEK2 1100delC; Colorectal cancer; Genetic susceptibility; IVS2+1G>A and I157T mutations

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CELL CYCLE CHECKPOINT KINASE 2 GENE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (BIRD);

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEIN-SERINE-THREONINE KINASES; REFERENCE VALUES; TURKEY; YOUNG ADULT;

EID: 84865865939     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.03.008     Document Type: Article

References (41)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Cheah P.Y. Recent advances in colorectal cancer genetics and diagnostics. Crit Rev Oncol Hematol 2009, 69(1):45-55.
3. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343(2):78-85.
4. Huxley R.R., Ansary-Moghaddam A., Clifton P., Czernichow S., Parr C.L., Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009, 125(1):171-180.
5. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48(4):526-535.
6. Hoshiyama Y., Sekine T., Sasaba T. A case-control study of colorectal cancer and its relation to diet, cigarettes, and alcohol consumption in Saitama Prefecture, Japan. Tohoku J Exp Med 1993, 171(2):153-165.
7. Tsong W.H., Koh W.P., Yuan J.M., Wang R., Sun C.L., Yu M.C. Cigarettes and alcohol in relation to colorectal cancer: the Singapore Chinese Health Study. Br J Cancer 2007, 96(5):821-827.
8. Antoni L., Sodha N., Collins I., Garrett M.D. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?. Nat Rev Cancer 2007, 7(12):925-936.
9. Bartek J., Falck J., Lukas J. CHK2 kinase - a busy messenger. Nat Rev Mol Cell Biol 2001, 2(12):877-886.
10. Bartek J., Chk1 Lukas J. Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3(5):421-429.
11. Cybulski C., Górski B., Huzarski T., Masojć B., Mierzejewski M., Debniak T., et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004, 75(6):1131-1135.
12. Brennan P., McKay J., Moore L., Zaridze D., Mukeria A., Szeszenia-Dabrowska N., et al. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum Mol Genet 2007, 16(15):1794-1801.
13. Seppälä E.H., Ikonen T., Mononen N., Autio V., Rökman A., Matikainen M.P., et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003, 89(10):1966.
14. Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286(5449):2528-2531.
15. Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K., et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003, 72(2):270-280.
16. Kleibl Z., Havranek O., Novotny J., Kleiblova P., Soucek P., Pohlreich P. Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations. Breast Cancer Res Treat 2008, 112(1):159-164.
17. Matsuoka S., Nakagawa T., Masuda A., Haruki N., Elledge S.J., Takahashi T. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res 2001, 61(14):5362-5365.
18. Djureinovic T., Lindblom A., Dalén J., Dedorson S., Edler D., Hjern F., et al. The CHEK2 1100C variant in Swedish colorectal cancer. Anticancer Res 2006, 26(6C):4885-4888.
19. van Engeland M., Derks S., Smits K.M., Meijer G.A., Herman J.G. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 2011, 29(10):1382-1391.
20. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004, 4:769-780.
21. Touvier M., Chan D.S., Lau R., Aune D., Vieira R., Greenwood D.C., et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011, 20(5):1003-1016.
22. Wan H., Zhou Y., Yang P., Chen B., Jia G., Wu X. Genetic polymorphism of glutathione S-transferase T1 and the risk of colorectal cancer: a meta-analysis. Cancer Epidemiol 2010, 34(1):66-72.
23. Wu X., Webster S.R., Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001, 276(4):2971-2974.
24. Meijers-Heijboer H., van den Ouweland A., Klijn J., Wasielewski M., de Snoo A., Oldenburg R., et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31(1):55-59.
25. Lipton L., Fleischmann C., Sieber O.M., Thomas H.J., Hodgson S.V., Tomlinson I.P., et al. Contribution of the CHEK2 1100C variant to risk of multiple colorectal adenoma and carcinoma. Cancer Lett 2003, 200(2):149-152.
26. Kilpivaara O., Laiho P., Aaltonen L.A., Nevanlinna H. CHEK2 1100C and colorectal cancer. J Med Genet 2003, 40(10):e110.
27. de Jong M.M., Nolte I.M., Te Meerman G.J., van der Graaf W.T., Mulder M.J., van der Steege G., et al. Colorectal cancer and the CHEK2 1100C mutation. Genes Chromosomes Cancer 2005, 43(4):377-382.
28. Kleibl Z., Havranek O., Hlavata I., Novotny J., Sevcik J., Pohlreich P., et al. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer 2009, 45(4):618-624.
29. Suchy J., Cybulski C., Wokołorczyk D., Oszurek O., Górski B., Debniak T., et al. CHEK2 mutations and HNPCC-related colorectal cancer. Int J Cancer 2010, 126(12):3005-3009.
30. Kilpivaara O., Alhopuro P., Vahteristo P., Aaltonen L.A., Nevanlinna H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006, 43(7):e34.
31. González-Hormazábal P., Castro V.G., Blanco R., Gómez F., Peralta O., Waugh E., et al. Absence of CHEK2 1100C mutation in familial breast cancer cases from a South American population. Breast Cancer Res Treat 2008, 110(3):543-545.
32. Martínez-Bouzas C., Beristain E., Guerra I., Gorostiaga J., Mendizabal J.L., De-Pablo J.L., et al. CHEK2 1100C is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat 2007, 103(1):111-113.
33. Narod S.A. Testing for CHEK2 in the cancer genetics clinic: ready for prime time?. Clin Genet 2010, 78(1):1-7.
34. CHEK2 Breast Cancer Case-Control Consortium CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9065 controls from 10 studies. Am J Hum Genet 2004, 74(6):1175-1182.
35. Nevanlinna H., Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006, 25(43):5912-5919.
36. Osorio A., Rodríguez-López R., Díez O., de la Hoya M., Ignacio Martínez J., Vega A., et al. The breast cancer low-penetrance allele 1100C in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 2004, 108(1):54-56.
37. Cybulski C., Wokołorczyk D., Huzarski T., Byrski T., Gronwald J., Górski B., et al. A deletion in CHEK2 of 5395bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 2007, 102(1):119-122.
38. Bogdanova N., Feshchenko S., Cybulski C., Dörk T. CHEK2 mutation and hereditary breast cancer. J Clin Oncol 2007, 25(19):e26.
39. Kilpivaara O., Vahteristo P., Falck J., Syrjäkoski K., Eerola H., Easton D., et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004, 111(4):543-547.
40. Cybulski C., Wokołorczyk D., Kładny J., Kurzawski G., Suchy J., Grabowska E., et al. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?. Eur J Hum Genet 2007, 15(2):237-241.
41. Cybulski C., Masojc B., Oszutowska D., Jaworowska E., Grodzki T., Waloszczyk P., et al. Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis 2008, 29(4):762-765.